Author

M. Sarracino

Observed names: Massimo Sarracino, SARRACINO M, SARRACINO M., Sarracino M, Sarracino M., Sarracino, Massimo

Institution: Roche (Italy)

Observed institutions: University of Campania "Luigi Vanvitelli", Fondazione Ricerca Molinette, Roche (Italy), University of Florence

OpenAlex ID: A5020811734

780 Predictors of Svr in Naive Hcv G1 Patients in Real Life Practice: the Probe

2008 · A. Craxi, F. Piccinino, et al. · Journal of Hepatology · 16

829 Effectiveness of Hepatitis C Virus Treatment in Real-life Practice: a Prospective Observational Multicenter Study in Italy (probe)

2008 · M. Rizzetto, M. Colombo, et al. · Journal of Hepatology · 9

P.229 HCV-1 subtypes and response to pegylated interferon plus ribavirin therapy

2006 · A. Alberti, M. Colombo, et al. · Journal of Clinical Virology · 4

PEG-IFN alfa-2a (40kd) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naïve patients with chronic hepatitis C (CHC)

2003 · G. Ideo, A. Attili, et al. · Journal of Hepatology · 4

[566] Pre-treatment Factors Predicting Sustained Virological Response in Treatment-naive Hcv Genotype 1 Patients Participating in a Large, Practice-based Nationwide Observational Study

2007 · A. Alberti, A. Ascione, et al. · Journal of Hepatology · 2

O.064 Antiviral treatment for hepatitis C virus infection in the real practice: A nationwide Italian experience (the PROBE study)

2006 · A. Alberti, A. Ascione, et al. · Journal of Clinical Virology · 2

AASLD Abstracts (pp. 687A-784A)

2003 · Gaetano Ideo, Sergio Babudieri, et al. · Hepatology · 2

602 the Candidate Hcv E1e2mf59 Vaccine Is Safe in Chronic Hepatitis C Patients and Accellerates the Second Phase Viral Decline Upon Primary Response to Peg-interferon-2a/ribavirin Therapy

2009 · P. Colombatto, M.R. Brunetto, et al. · Journal of Hepatology · 1

Pegylated 40KDA IFN alfa-2a plus amantadine (AMA) or ribavirin (RBV) in naives with chronic hepatitis C (CHC): the HIMPCT (Hepatitis Italian Multicenter Pegasys Amantadine Cooperative Trial)

2002 · Gaetano Ideo, Mario Angelico, et al. · Journal of Hepatology · 1

NodolaseTM: A Review of Efficacy

2017 · Sarracino, Massimo · Zenodo (CERN European Organization for Nuclear Research)

Nodolase: A Review of Efficacy

2017 · M. Sarracino · Research and reviews : journal of medical and health sciences/Research an reviews : journal of medical and health sciences

The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin

2009 · P. Colombatto, M.R. Brunetto, et al. · Digestive and Liver Disease

[643] Outcome of Peg-interferon Plus Ribavirin Treatment in Patients Affected by Hcv (a Comparison Between Genotype 2 and 3): Considerations From Italian National Observational Study (probe)

2007 · P. Grima, A. Orani, et al. · Journal of Hepatology

[629] the Influence of Obesity and Diabetes on Clinical and Therapeutical Outcome in Hcv Related Chronic Hepatitis: an Italian Nationwide Survey Study (probe Group)

2007 · M. Persico, M. Masarone, et al. · Journal of Hepatology

[567] Hcv Hepatitis and Interferon-related Depression: an Analysis of the Retrospective Phase of the Probe Study

2007 · P. Amodio, S. Montebianco Abenavoli, et al. · Journal of Hepatology

HCV hepatitis and interferon-related depression: An analysis of the retrospective phase of the Probe study

2007 · Amodio P, Montebianco Abenavoli S, et al. · UnissResearch (Università degli Studi di Sassari)

PEG-IFN alfa-2a (40KD) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)

2003 · Ideo G, Antonucci G, et al. · UnissResearch (Università degli Studi di Sassari)

Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a.

2001 · Patrizia Farci, Giancarlo Serra, et al.

Works count: 26

Citation count: 43

H-index: 4

I10-index: 1